Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.


Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

 

International journal of endocrinology Том 15, №3, 2019

Back to issue

Diabetes mellitus and Alzheimer’s disease

Authors: Pashkovska N.V. (1), Pankiv V.I. (2), Grinko N.V. (1), Pashkovska O.V. (3)
1 - Bukovinian State Medical University, Chernivtsi, Ukraine
2 - Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
3 - Charles University in Prague, Prague, the Czech Republic

Categories: Endocrinology

Sections: Specialist manual

print version


Summary

В оглядовій статті наведені сучасні відомості щодо епідеміології та чинників ризику розвитку хвороби Альцгеймера при цукровому діабеті. Проаналізовано дані літератури щодо основних патогенетичних ланок розвитку нейродегенеративних порушень у пацієнтів із цукровим діабетом, а також механізмів взаємообтяження. Наведені результати клінічних та експериментальних досліджень щодо можливостей патогенетичної корекції когнітивних порушень при хворобі Альцгеймера, яка перебігає на тлі цукрового діабету, зазначені найбільш перспективні напрямки наукових досліджень із цієї проблеми.

В обзорной статье приведены современные сведения об эпидемиологии и факторах риска развития болезни Альцгеймера при сахарном диабете. Проанализированы данные литературы по основным патогенетическим звеньям развития нейродегенеративных нарушений у пациентов с сахарным диабетом, а также механизмам взаимоотягощения. Представлены результаты клинических и экспериментальных исследований относительно возможностей патогенетической коррекции когнитивных нарушений при болезни Альцгеймера, которая протекает на фоне сахарного диабета, указаны наиболее перспективные направления научных исследований по данной проблеме.

The article reviews modern information on epidemiology and risk factors for Alzheimer’s disease in diabetes mellitus. The literature data on the main pathogenetic links of the development of neurodegenerative disorders in diabetic patients, as well as the mechanisms of mutual burden are analyzed. The article deals with the results of clinical studies on the possibilities of pathogenetic correction of cognitive disorders in Alzheimer’s disease, which runs on the background of diabetes mellitus.


Keywords

цукровий діабет; хвороба Альцгеймера; когнітивні порушення; огляд

сахарный диабет; болезнь Альцгеймера; когнитивные нарушения; обзор

diabetes mellitus; Alzheimer’s disease; cognitive disorders; review


For the full article you need to subscribe to the magazine.


Bibliography

1. Dementia. Fact sheet [Електронний ресурс] // World Health Organization. — 2017. — Режим доступу: www.who.int/mediacentre/factsheets/fs362/en/
2. Riederer P., Korczyn A.D., Ali S.S. et al. The diabetic brain and cognition // Journal of Neural Transmission. — 2017. — Vol.124(11). — P. 1431-1454. PMID 28766040. doi: 10.1007/s00702-017-1763-2.
3. Gudala K., Bansal D., Schifano F., Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies // J. of Diabetes Investigation. — 2013. — Vol. 4(6). — P. 640-650. doi: 10.1111/jdi.12087.
4. Ott A., Stolk R.P., Van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study // Neurology. — 1999. — Vol. 53(9). — P. 1937-42.
5. Cheng G., Huang C., Deng H., Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies // Intern. Med. J. — 2012. — Vol. 42(5). — P. 484-91.
6. Samaras K., Sachdev P.S. Diabetes and the elderly brain: sweet memories? // Therapeutic Advances in Endocrino–logy and Metabolism. — 2012. — Vol. 3(6). — P. 189-196. doi: 10.1177/2042018812469645.
7. Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике // Медицинский совет. — 2015. — № 18. — С. 41-45.
8. Lane C.A., Hardy J., Schott J.M. Alzheimer’s disease // Eur. J. Neurol. — 2018. — Vol. 25(1) — P. 59-70. doi: 10.1111/ene.13439.
9. Bermejo-Pareja F., Benito-León J., Vega S. et al. Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain // J. Neurol. Sci. — 2008. — Vol. 264(1-2). — P. 63-72.
10. Dodd G.T., Tiganis T. Insulin action in the brain: Roles in energy and glucose homeostasis // J. Neuroendocrinol. — 2017. — Vol. 29(10). — P. 1-13. doi: 10.1111/jne.12513.
11. Costello D.A., Claret M., Al-Qassab H. et al. Brain Deletion of Insulin Receptor Substrate 2 Disrupts Hippocampal Sy–naptic Plasticity and Metaplasticity / Ed. by T. Amédée // PLoS ONE. — 2012. — Vol. 7(2). — e31124. doi: 10.1371/journal.pone.0031124.
12. Crane P.K., Walker R., Hubbard R.A. et al. Glucose Levels and Risk of Dementia // The New England Journal of Medicine. — 2013. — Vol. 369(6). — P. 540-548. doi: 10.1056/NEJMc1311765.
13. Abbatecola A.M., Rizzo M.R., Barbieri M. et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics // Neurology. —2006. — Vol. 67. — P. 235-240.
14. Shukla V., Shakya A.K., Perez-Pinzon M.A., Dave K.R. Cerebral ischemic damage in diabetes: an inflammatory perspective // Journal of Neuroinflammation. — 2017. — Vol. 14. — P. 21. doi: 10.1186/s12974-016-0774-5.
15. Auer R.N. Hypoglycemic brain damage // Metab. Brain Dis. — 2004. — Vol. 19(3–4). — P. 169-75.
16. Yun J.-S., Ko S.-H. Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus // Diabetes & Metabolism Journal. — 2016. — Vol. 40(6). — P. 423-432. doi: 10.4093/dmj.2016.40.6.423.
17. Feinkohl I., Aung P.P., Keller M. et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study // Diabetes Care. — 2014. — Vol. 37(2). — P. 507-15. doi: 10.2337/dc13-1384.
18. De Galan B.E., Zoungas S., Chalmers J. et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial // Diabetologia. — 2009. — Vol. 52(11). — P. 2328-2336. doi: 10.1007/s00125-009-1484-7.
19. Laws S.M., Gaskin S., Woodfield A. et al. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults // Scientific Reports. — 2017. — Vol. 7. — P. 9766. doi: 10.1038/s41598-017-09577-4.
20. Bernstein L.H. Brain and Cognition [Електронний ресурс] / L.H. Bernstein // Medicine and Life Sciences Scientific Journal. — 2015. — Режим доступу: www.pharmaceuticalintelligence.com/2015/10/14/brain-and-cognition.
21. De la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease // Biochemical pharmacology. — 2014. — Vol. 88(4). — P. 548-559. doi: 10.1016/j.bcp.2013.12.012.
22. Derakhshan F., Toth C. Insulin and the brain // Curr. Diabetes Rev. — 2013. — Vol. 9(2). — P. 102-16.
23. Hormonal signaling systems of the brain in diabetes mellitus. Neurodegenerative Diseases / A. Shpakov [et al.] / Ed. by R.C.-C. Chang. — Intech Open Access Publisher, Rijeka, Croatia, 2011. — P. 349-386. doi: 10.5772/28930.
24. Kleinridders A., Ferris H.A., Cai W., Kahn C.R. Insulin Action in Brain Regulates Systemic Metabolism and Brain Function // Diabetes. — 2014. — Vol. 63(7). — P. 2232-2243. doi: 10.2337/db14-0568.
25. Leszek J., Trypka E., Tarasov V. et al. Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease // Current topics in medicinal chemistry. — 2017. — Vol. 17, № 12. — P. 1331-1335.
26. Pivovarova O. et al. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer’s disease? // Annals of Medicine. — 2016. — Vol. 48, № 8. — P. 614-624.
27. Roostaei T., Nazeri A., Felsky D. et al. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer’s disease // Mol. Psychiatry. — 2016. — Vol. 22(2). — P. 287-295. doi: 10.1038/mp.2016.35.
28. Zhu H., Xue X., Wang E. et al. Amylin receptor ligands reduce the pathological cascade of Alzheimer’s disease // Neuropharmacology — 2017. — Vol. 119. — P. 170-181. doi: 10.1016/j.neuropharm.2017.03.030.
29. Jackson K., Barisone G.A., Diaz E., Jin L.W., DeCarli C., Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? // Ann. Neurol. — 2013. — Vol. 74(4). — P. 517-526. doi: 10.1002/ana.23956.
30. Zhu H., Stern R., Tao Q. et al. An amylin analog used as a challenge test for Alzheimer’s disease // Alzheimer’s & Dementia: Translational Research & Clinical Interventions. — 2017. — Vol. 3 — P. 33-43. doi: 10.1016/j.trci.2016.12.002.
31. Williamson J.D., Launer L.J., Bryan R.N. et al. Cognitive Function and Brain Structure in Persons with Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial // JAMA Internal Medicine. — 2014. — Vol. 174(3). — P. 324-333. doi: 10.1001/jamainternmed.2013.13656.
32. Wu J.H., Haan M.N., Liang J., Ghosh D., Gonzalez H.M., Herman W.H. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study // Ann. Epidemiol. — 2003. — Vol. 13(5). — P. 369-76.
33. Weinstock R.S., Teresi J.A., Goland R. et al. Glycemic Control and Health Disparities in Older Ethnically Diverse Underserved Adults with Diabetes: Five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study // Diabetes Care. — 2011. — Vol. 34(2). — P. 274-279. doi: 10.2337/dc10-1346.
34. Launer L.J., Miller M.E., Williamson J.D. et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study // Lancet Neurology. — 2011. — Vol. 10(11). — P. 969-977. doi: 10.1016/ S1474-4422(11)70188-0.
35. Пашковська Н.В. Когнітивні порушення при цукровому діабеті типу 2: роль гіпоглікемізуючої терапії / Н.В. Пашковська // Міжнародний ендокринологічний журнал. — 2018. — Т. 14, № 1. — С. 76-85. — Режим доступу: www.nbuv.gov.ua/UJRN/Mezh_2018_14_1_18.
36. Plastino M., Fava A., Pirritano D. et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer’s disease and diabetes mellitus type-2 // J. Neurol. Sci. — 2010. — Vol. 288(1–2). — P. 112-6. doi: 10.1016/j.jns.2009.09.022.
37. Craft S., Baker L.D., Montine T.J. et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment // Archives of Neurology. — 2012. — Vol. 69(1). — P. 29-38. doi: 10.1001/archneurol.2011.233.
38. Wang Y.-W., He S.-J., Feng X. et al. Metformin: a review of its potential indications // Drug Design, Development and The–rapy. — 2017. — Vol. 11. — P. 2421-2429. doi: 10.2147/DDDT.S141675.
39. Markowicz-Рiasecka M., Sikora J., Szydłowska A., Skupień A., Mikiciuk-Оlasik E., Huttunen K.M. Metformin — a Future Therapy for Neurodegenerative Diseases // Pharm. Res. — 2017. — Vol. 34(12). — P. 2614-2627. doi: 10.1007/s11095-017-2199-y.
40. Fatt M., Hsu K., He L. et al. Metformin Acts on Two Different Molecular Pathways to Enhance Adult Neural Precursor Proliferation/Self-Renewal and Differentiation // Stem Cell Reports. — 2015. — Vol. 5(6). — P. 988-995. doi: 10.1016/j.stemcr.2015.10.014.
41. Ge X.H., Zhu G.J., Geng D.Q. et al. Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/ JNK3 signaling pathways in rats // Physiol. Behav. — 2017. — Vol. 170. — P. 115-123. doi: 10.1016/j.physbeh.2016.12.021.
42. Pintana H., Apaijai N., Pratchayasakul W., Chattipa–korn N., Chattipakorn S.C. Effects of metformin on lear–ning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats // Life Sci. — 2012. — Vol. 91(11–12). — P. 409-14. doi: 10.1016/j.lfs.2012.08.017.
43. Hettich M.M., Matthes F., Ryan D.P. et al. The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex / Ed. by H.K. Paudel // PLoS ONE. — 2014. — Vol. 9(7). — e102420. doi: 10.1371/journal.pone.0102420.
44. Bibi F., Ullah I., Kim M.O., Naseer M.I. Metformin attenuate PTZ-induced apoptotic neurodegeneration in human cortical neuronal cells // Pakistan Journal of Medical Scien–ces. — 2017. — Vol. 33(3). — P. 581-585. doi: 10.12669/pjms.333.11996.
45. Markowicz-Piasecka M., Sikora J., Mateusiak Ł., Mikiciuk-Olasik E., Huttunen K.M. Metformin and Its Sulfo–namide Prodrugs Inhibit Human Cholinesterase Activity // Oxidative Medicine and Cellular Longevity. — 2017. — 7303096. doi: 10.1155/2017/7303096.
46. Kuan Y.C., Huang K.W., Lin C.L., Hu C.J., Kao C.H. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus // Prog. Neuropsychopharmacol. Biol. Psychiatry. — 2017. — Vol. 79 (Pt B). — P. 77-83. doi: 10.1016/j.pnpbp.2017.06.002.
47. Koenig A.M., Mechanic-Hamilton D., Xie S.X. et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data from a Randomized Placebo-controlled Crossover Study // Alzheimer Dis. Assoc. Disord. — 2017. — Vol. 31(2). — P. 107-113. doi: 10.1097/WAD.0000000000000202.
48. Imfeld P., Bodmer M., Jick S.S., Meier C.R. Metformin, other antidiabetic drugs, and risk of Alzheimer’s di–sease: a population-based case-control study // J. Am. Geriatr. Soc. — 2012. — Vol. 60(5). — P. 916-921. doi: 10.1111/j.1532-5415.2012.03916.x.
49. Moore E.M., Mander A.G., Ames D. et al. Increased Risk of Cognitive Impairment in Patients with Diabetes Is Associated with Metformin // Diabetes Care. — 2013. — Vol. 36(10). — P. 2981-2987. doi: 10.2337/dc13-0229.
50. Жердева Н. Новая страница в назначении метформина // Практикуючий лікар. — 2015. — № 1. — С. 65-67.
51. Seaquist E.R., Miller M.E., Fonseca V. et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORDMIND // Journal of Diabetes and its Complications. — 2013. — Vol. 27(5). — P. 485-491. doi: 10.1016/j.jdiacomp.2013.03.005.
52. Cheng C., Lin C.H., Tsai Y.W., Tsai C.J., Chou P.H., Lan T.H. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis // J. Gerontol. A Biol. Sci Med. Sci. — 2014. — Vol. 69(10). — P. 1299-1305. doi: 10.1093/gerona/glu073.
53. Fu H., Xie W., Curtis B., Schuster D. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis // Curr. Med. Res. Opin. — 2014. — Vol. 29. — P. 1-7. doi: 10.1185/03007995.2014.922944.
54. Orkaby A.R., Cho K., Cormack J., Gagnon D.R., Dri–ver J.A. Metformin vs sulfonylurea use and risk of dementia in US veterans aged 65 years with diabetes // Neurology. — 2017. doi: 10.1212/WNL.0000000000004586.
55. Cai X.-S., Tan Z.-G., Li J.-J. et al. Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats // Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. — 2017. — Vol. 23. — P. 4334-4342. doi: 10.12659/MSM.903252.
56. Li Y., Duffy K.B., Ottinger M.A. et al. GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer’s Disease // Journal of Alzheimer’s disease. — 2010. — Vol. 19(4). — P. 1205-1219. doi: 10.3233/JAD-2010-1314.
57. Velmurugan K., Bouchard R., Mahaffey G. et al. Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells // J. Neurochem. — 2012. — Vol. 123. — P. 919-931. doi: 10.1111/jnc.12036.
58. Hansen H.H., Fabricius K., Barkholt P. et al. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease / Ed. by J. Padmanabhan // PLoS ONE. — 2016. — Vol. 11(7). — e0158205. doi: 10.1371/journal.pone.0158205.
59. Kosaraju J., Holsinger R.M., Guo L., Tam K.Y. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzhei–mer’s Disease // Mol. Neurobiol. — 2017. — Vol. 54(8). — P. 6074-6084.
60. Jain S., Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia // Physiol. Behav. — 2015. — Vol. 152(Pt A). — P. 182-93. doi: 10.1016/j.physbeh.2015.09.007.
61. Lin B., Koibuchi N., Hasegawa Y. et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice // Cardiovascular Diabetology. — 2014. — Vol. 13. — P. 148. doi: 10.1186/s12933-014-0148-1.
62. Rizvi S.M., Shakil S., Biswas D. et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease — diabetes type 2 linkage via an enzoinformatics study // CNS Neurol. Disord. Drug Targets. — 2014. — Vol. 13(3). — P. 447-51.
63. Shaikh S., Rizvi S.M., Shakil S., Riyaz S., Biswas D., Jahan R. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders // Biotechnol. Appl. Biochem. — 2016. — Vol. 63(1). — P. 145-50. doi: 10.1002/bab.1319.
64. Qiu W.Q. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease // Neuroscience. — 2017. — Vol. 356. — P. 44-51. doi: 10.1016/j.neuroscience.2017.05.024.
65. Zhang N., Yang S., Wang C. et al. Multiple target of hAmylin on rat primary hippocampal neurons // Neuropharmacology. — 2017. — Vol. 113. — P. 241-251. doi: 10.1016/j.neuropharm.2016.07.008.

Similar articles

Cognitive impairment in patients with type 2 diabetes mellitus: the role of hypoglycemic therapy
Authors: Пашковська Н.В.
Вищий державний навчальний заклад України «Буковинський державний медичний університет», м. Чернівці, Україна

International journal of endocrinology Том 14, №1, 2018
Date: 2018.05.04
Categories: Endocrinology
Sections: Specialist manual
The influence of peripheral diabetic sensorimotor neuropathy on the state of cognitive function in elderly patients with type 2 diabetes mellitus
Authors: Жердьова Н.М.
Національна медична академія післядипломної освіти імені П.Л. Шупика, м. Київ, Україна

International journal of endocrinology Том 13, №4, 2017
Date: 2017.07.18
Categories: Endocrinology
Sections: Clinical researches
The Influence of Metformin on the Indices of Thyroid Panel, Carbohydrate and Lipid Metabolism in Patients with Diffuse Toxic Goiter and Insulin Resistance
Authors: Lishchuk O.Z. - Lviv National Medical University named after Danylo Halytskyi, Department of Endocrinology, Lviv, Ukraine
International journal of endocrinology 1 (73) 2016
Date: 2016.03.25
Categories: Endocrinology
Sections: Clinical researches

Back to issue